Interferon deficiency can lead to severe COVID.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2021
   Pooled it
2. Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles.Scientific reports · 2023
   Trial
3. An enhanced IL17 and muted type I interferon nasal epithelial cell state characterizes severe COVID-19 with fungal coinfection.Microbiology spectrum · 2024
   Article
4. Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract.Proceedings of the National Academy of Sciences of the United States of America · 2024
   Article
5. Navigating the Post-COVID-19 Immunological Era: Understanding Long COVID-19 and Immune Response.Life (Basel, Switzerland) · 2023
   Review
6. Determinants of COVID-19 Disease Severity-Lessons from Primary and Secondary Immune Disorders including Cancer.International journal of molecular sciences · 2023
   Review
7. Geographical distribution of host's specific SARS-CoV-2 mutations in the early phase of the COVID-19 pandemic.Gene · 2023
   Article
8. Immune profiles to distinguish hospitalized versus ambulatory COVID-19 cases in older patients.iScience · 2022
   Article
9. SARS-CoV-2 spike protein induces a differential monocyte activation that may contribute to age bias in COVID-19 severity.Scientific reports · 2022
   Article
10. Pin-Pointing the Key Hubs in the IFN-γ Pathway Responding to SARS-CoV-2 Infection.Viruses · 2022
    Article
11. Clinical implications of host genetic variation and susceptibility to severe or critical COVID-19.Genome medicine · 2022
    Review
12. Differentially expressed plasmatic microRNAs in Brazilian patients with Coronavirus disease 2019 (COVID-19): preliminary results.Molecular biology reports · 2022
    Article
13. Airway epithelial interferon response to SARS-CoV-2 is inferior to rhinovirus and heterologous rhinovirus infection suppresses SARS-CoV-2 replication.Scientific reports · 2022
    Article
14. Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells.Journal of virology · 2022
    Article
15. Obesity and Leptin Resistance in the Regulation of the Type I Interferon Early Response and the Increased Risk for Severe COVID-19.Nutrients · 2022
    Review
16. Parsing the role of NSP1 in SARS-CoV-2 infection.bioRxiv : the preprint server for biology · 2022
    Article
17. SARS-CoV-2 infection and oxidative stress: Pathophysiological insight into thrombosis and therapeutic opportunities.Cytokine & growth factor reviews · 2022
    Review
18. A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice.The Journal of experimental medicine · 2022
    Article
19. Distinct systemic immune networks define severeFrontiers in immunology · 2022
    Article
20. An Updated Review on Complicated Mechanisms of COVID-19 Pathogenesis and Therapy: Direct Viral Damage, Renin-angiotensin System Dysregulation, Immune System Derangements, and Endothelial Dysfunction.Infectious disorders drug targets · 2022
    Article

Corrections and comments

• Comment on
  Autoantibodies against type I IFNs in patients with life-threatening COVID-19.2020
• Comment on
  Susceptibility to severe COVID-19.2020

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as